论文部分内容阅读
第三代芳香化酶抑制剂显著、特异抑制雌激素的合成,已批准用于绝经后乳腺癌妇女,但在绝经前单独应用常不能完全阻断卵巢合成雌激素。在早卵泡期使用可诱导排卵,绝经前长期应用则雌激素稳定在较低的水平。芳香化酶抑制剂显著抑制腺体外来源的雌激素,治疗中重度子宫内膜异位症。在辅助生育中可以取代氯米芬,节省卵泡刺激素(FSH)的用量,避免卵巢过度刺激,提高卵巢反应及用于体外成熟。来曲唑还可以诱导出多囊卵巢的动物模型。
Third-generation aromatase inhibitors significantly and especially inhibit estrogen synthesis and have been approved for use in postmenopausal women with breast cancer, but single-use before menopause often fails to completely block ovarian synthesis of estrogen. In the early follicular phase can induce ovulation, long-term use of pre-menopausal estrogen stabilized at a lower level. Aromatase inhibitors significantly inhibit estrogen extragalactic origin for the treatment of moderate-severe endometriosis. In assisted reproductive can replace clomiphene, save the amount of follicle stimulating hormone (FSH), to avoid ovarian hyperstimulation, improve ovarian response and for in vitro maturation. Letrozole can also induce polycystic ovary animal models.